Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Dec 15, 2025; 17(12): 112853
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.112853
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.112853
Long-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab: A case report
Jun Pan, Yi-Tian Chen, Xiao-Yuan Chu, Department of Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China
Ping Li, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
Yu-He Zhou, Ting-Ting Pan, Department of General Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China
Co-first authors: Jun Pan and Ping Li.
Co-corresponding authors: Yi-Tian Chen and Xiao-Yuan Chu.
Author contributions: Pan J and Li P drafted the manuscript and made equal contributions as co-first authors; Li P acquired the data; Pan J analyzed and interpreted pathology; Zhou YH and Pan TT analyzed and interpreted the imaging findings; Pan J, Chen YT, and Chu XY contributed to the study conception and design; Chen YT and Chu XY made equal contributions as co-corresponding authors; all authors approved the final version to publish.
Informed consent statement: Written informed consent was obtained from the participant.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Yuan Chu, MD, Department of Oncology, Jinling Hospital, Medical School of Nanjing University, No. 305 Zhongshan East Road, Nanjing 210002, Jiangsu Province, China. chuxiaoyuan0@163.com
Received: August 8, 2025
Revised: September 5, 2025
Accepted: October 20, 2025
Published online: December 15, 2025
Processing time: 126 Days and 2.6 Hours
Revised: September 5, 2025
Accepted: October 20, 2025
Published online: December 15, 2025
Processing time: 126 Days and 2.6 Hours
Core Tip
Core Tip: Chemotherapy combined with immunotherapy is the standard first-line treatment for metastatic gastric cancer. However, the first-line median progression-free survival is only about 7 months. This article reports a case of metastatic gastric cancer in which the patient received S-1 plus oxaliplatin regimen with sintilimab, followed by maintenance therapy with S-1 and sintilimab. The patient achieved a partial response and a progression-free survival of 23 months. Moreover, the treatment was temporarily paused for 6 months due to pneumonia. However, upon re-evaluation 6 months later, the tumor continued to regress. This combination therapy has shown encouraging results and warrants further study.